Table 1.
Demographics and clinical characteristics of the NF-PanNETs cohort and each subgroup.
| Characteristics | Study Cohort (n = 509) |
Group 1 (n = 394) |
Group 2 (n = 114) |
Group 3 (n = 40) |
Group 4 (n = 179) |
Group 5 (n = 23) |
|---|---|---|---|---|---|---|
| No. (%) | ||||||
| Gender | ||||||
| Male | 222 (43.6) | 169 (42.9) | 53 (46.5) | 13 (32.5) | 70 (39.1) | 12 (52.2) |
| Female | 287 (56.4) | 225 (57.1) | 61 (53.5) | 27 (67.5) | 109 (60.9) | 11 (47.8) |
| Median Age, years | 54 | 55 | 50.0 | 56.5 | 55.0 | 52.0 |
| Tumor size, cm | ||||||
| Mean (SD) | 3.6 (2.7) | 3.1 (2.4) | 5.4 (3.0) | 3.8 (2.2) | 1.4 (0.4) | 4.1 (3.2) |
| Location | ||||||
| Head | 147 (28.9) | 118 (29.9) | 28 (24.6) | 8 (20.0) | 47 (26.3) | 0 (0.0) |
| Neck | 65 (12.8) | 58 (14.7) | 7 (6.1) | 4 (10.0) | 34 (19.0) | 0 (0.0) |
| Body | 74 (14.5) | 62 (15.7) | 12 (10.5) | 5 (12.5) | 33 (18.4) | 0 (0.0) |
| Tail | 82 (16.1) | 48 (12.2) | 34 (29.8) | 5 (12.5) | 22 (12.3) | 0 (0.0) |
| Body-Tail | 118 (23.2) | 87 (22.1) | 31 (27.2) | 13 (32.2) | 34 (19.0) | 0 (0.0) |
| Multifocal | 23 (4.5) | 21 (5.3) | 2 (1.8) | 5 (12.5) | 9 (5.0) | 23 (100.0) |
| Lymph node positive | n = 470 | n = 76 | n = 176 | n = 22 | ||
| Yes | 98 (20.9) | 55 (14.0) | 43 (56.6) | 9 (22.5) | 12 (6.8) | 6 (27.3) |
| No | 372 (79.1) | 339 (86.0) | 33 (43.4) | 31 (77.5) | 164 (93.2) | 16 (72.7) |
| Perineural invasion | n = 470 | n = 387 | n = 71 | n = 39 | n = 176 | n = 22 |
| Yes | 88 (19.2) | 49 (12.7) | 39 (54.9) | 4 (10.3) | 17 (9.7) | 8 (36.4) |
| No | 370 (80.8) | 338 (87.3) | 32 (45.1) | 35 (89.7) | 159 (90.3) | 14 (63.6) |
| Microvascular invasion | n = 458 | n = 387 | n = 71 | n = 39 | n = 176 | n = 22 |
| Yes | 116 (25.3) | 73 (18.9) | 43 (60.6) | 13 (33.3) | 20 (11.4) | 4 (18.2) |
| No | 342 (74.7) | 314 (81.1) | 28 (39.4) | 26 (66.7) | 156 (88.6) | 18 (81.8) |
| Metastases | n = 114 | n = 5 | n = 11 | n = 2 | ||
| Liver | 111 (97.4) | 0 (0.0) | 111 (97.4) | 5 (100.0) | 11 (100.0) | 2 (100.0) |
| Peritoneum/others | 3 (2.6) | 0 (0.0) | 3 (2.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Surgical approach | n = 464 | n = 70 | n = 176 | n = 22 | ||
| Open | 369 (79.5) | 305 (77.4) | 64 (91.4) | 34 (85.0) | 128 (72.7) | 19 (86.4) |
| Minimally invasive | 95 (20.5) | 89 (22.6) | 6 (8.6) | 6 (15.0) | 48 (27.3) | 3 (13.6) |
| Surgical procedure | n = 464 | n = 503 | n = 70 | n = 176 | n = 22 | |
| PD | 141 (30.4) | 129 (32.7) | 12 (17.1) | 12 (30.0) | 52 (29.5) | 8 (36.4) |
| DP | 268 (57.8) | 213 (54.1) | 55 (78.6) | 25 (62.5) | 92 (52.3) | 10 (45.5) |
| TP | 10 (2.2) | 8 (2.0) | 2 (2.9) | 1 (2.5) | 0 (0.0) | 4 (18.2) |
| EN | 36 (7.8) | 35 (8.9) | 1 (1.4) | 1 (2.5) | 26 (14.8) | 0 (0.0) |
| CP | 9 (1.9) | 9 (2.3) | 0 (0.0) | 1 (2.5) | 6 (3.4) | 0 (0.0) |
| Margin status | n = 464 | n = 70 | n = 176 | n = 22 | ||
| R0 | 387 (83.4) | 387 (98.2) | 0 (0.0) | 35 (87.5) | 167 (94.9) | 21 (95.5) |
| R1 | 7 (1.5) | 7 (1.8) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 0 (0.0) |
| R2 | 70 (15.1) | 0 (0.0) | 70 (100.0) | 5 (12.5) | 8 (4.5) | 1 (4.5) |
| AJCC 8th TNM stage | ||||||
| I | 135 (26.5) | 135 (34.3) | 0 (0.0) | 6 (15.0) | 134 (74.9) | 4 (17.4) |
| II | 204 (40.1) | 203 (51.5) | 0 (0.0) | 23 (57.5) | 25 (14.0) | 12 (52.2) |
| III | 56 (11.0) | 56 (14.2) | 0 (0.0) | 6 (15.0) | 9 (5.0) | 5 (21.7) |
| IV | 114 (22.4) | 0 (0.0) | 114 (100.0) | 5 (12.5) | 11 (6.1) | 2 (8.7) |
| WHO classification | ||||||
| G1 | 217 (42.6) | 201 (51.0) | 15 (13.2) | 13 (32.5) | 122 (68.2) | 10 (43.5) |
| G2 | 269 (52.8) | 184 (46.7) | 85 (74.6) | 26 (65.0) | 54 (30.2) | 12 (52.2) |
| G3 | 23 (4.5) | 9 (2.3) | 14 (12.3) | 1 (2.5) | 3 (1.7) | 1 (4.3) |
SD: standard deviation; PD: pancreaticoduodenectomy; DP: distal pancreatectomy; TP: total pancreatectomy; EN: enucleation; CP: central pancreatectomy; AJCC: American Joint Committee on Cancer; WHO: World Health Organization.